Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7517360 | 0.87 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL7077870 | 0.87 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL8080894 | 0.86 | P2RX7 (0.56) | P2RX7 | |
| SCHEMBL7690936 | 0.86 | P2RX7 (0.73) | P2RX7 | |
| SCHEMBL4095273 | 0.86 | P2RX7 (0.56) | P2RX7 | |
| SCHEMBL4129828 | 0.84 | P2RX7 (0.77) | P2RX7 | |
| SCHEMBL8080956 | 0.84 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL8084055 | 0.84 | HSD17B10 (0.56) | P2RX7HPGD | |
| SCHEMBL8071731 | 0.84 | P2RX7 (0.65) | P2RX7 | |
| SCHEMBL7556017 | 0.84 | P2RX7 (0.53) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881754-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-19 | — | — | US | disclosed |
| US-20030013704-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| EP-1242364-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044170-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013704-A1 | Adamantane derivatives | ADRA2C, CHRNA2, ADRA1D | P2RX7 1500/4885HPGD 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.